No Detail Found!

Effects of PCSK9 Inhibitors on Glucose Metabolism in Hyperlipidaemic Patients: A Meta-Analysis

Author(s)
Yujie Bai Department of Nephrology, The First Affiliated Hospital of Soochow University,Suzhou,China
Miao Hu Department of Nephrology, The First Affiliated Hospital of Soochow University,Suzhou,China
Jiayan Zhang Department of Nephrology, The First Affiliated Hospital of Soochow University,Suzhou,China
Ling Zhou Department of Nephrology, The First Affiliated Hospital of Soochow University,Suzhou,China
Abstract
This review assessed the impacts of PCSK9 inhibitors on glucose metabolism in patients with dyslipidaemia. A comprehensive search was conducted using PubMed, Embase, Cochrane Library, and ClinicalTrials.gov to nd randomised controlled studies investigating the indicators of glucose metabolism. All RCTs comparing PCSK9 inhibitors with other lipid-lowering drugs or placebo from January 2018 to December 2023 were included. In total, 12 randomised controlled trials were included, and the authors used a xed-e ects model to evaluate the potential impacts of PCSK9 inhibitors on glucose metabolism. Compared with the control group, FPG (MD = 0.08, 95% CI -0.07~0.24) and HbAlc (SMD = 0.02, 95% CI -0.09~0.12) slightly increased in patients treated with PCSK9 inhibitors, with no statistical signi cance. The PCSK9 inhibitor group also did not exhibit a statistically signi cant di erence in risk between deteriorating pre-existing diabetes (RR = 0.92, 95% CI 0.84-1.01) and developing new-onset diabetes (RR = 0.95, 95% CI 0.86-1.05) from the control group. The results were not a ected by the type of PCSK9 inhibitors or treatment duration.
Publication Details
Page(s) 486-493
Published Journal: Journal of the College of Physicians and Surgeons Pakistan, Volume: 35, Issue: 04, Year: 2025

Request the full text from PASTIC

Keywords
Diabetes mellitus, Glucose metabolism, Diabetes mellitus, PCSK9 inhibitors
References
Navarese EP,Robinson JG,Kowalewski M,Kolodziejczak M,Andreotti F,Bliden K .2018 .Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: A systematic review and meta-analysis. JAMA, 2525(15) : 1566-79.
Collaboration CTT,Fulcher J,O'Connell R,Voysey M,Emberson J,Blackwell L .2015 .E cacy and safety of LDLlowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet, 6736(14) : 61368-4.
Abifadel M,Varret M,Rabes JP,Allard D,Ouguerram K,Devillers M .2003 .Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet, 10(2) : 154-6.
Denis M,Marcinkiewicz J,Zaid A,Gauthier D,Poirier S,Lazure C .2012 .Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation, 10(7) : 894-901.
Ference BA,Robinson JG,Brook RD,Catapano AL,Chapman MJ,Ne DR .2016 .Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med, 10(22) : 2144-53.
de Carvalho LSF,Campos AM,Sposito AC .2018 .Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: A systematic review and metaanalysis with over 96,000 patient-years. Diabetes Care, 10(2) : 1464-7.
Monami M,Sesti G,Mannucci E. .2019 .PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes Metab, 10(4) : 903-8.
Moher D,Liberati A,Tetzla J,Altman DG .2009 .6(7): e1000097. PLoS Med, 1000097 : .
Higgins JP,Altman DG,Gotzsche PC,Juni P,Moher D,Oxman AD .2011 .The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 10 : .
Ray KK,Leiter LA,Wieland DM,Cariou B,Colhoun HM,Henry RR .2018 .Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomised trial. Diabetes Obes Metab, 10(6) : 1479-89.
Burggraaf B,Pouw NMC,Arroyo SF,der Zee LCV,de Geijn GMv,Birnie E .2020 .A placebo-controlled proof-of-concept study of alirocumab on postprandial lipids and vascular elasticity in insulin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab, 10(5) : 807-16.
Rosenson RS,Daviglus ML,Handelsman Y,Pozzilli P,Bays H,Monsalvo MLe .2019 .t a.l E cacy and safety of evolocumab in individuals with type 2 diabetes mellitus: Primary results of the randomised controlled BANTING study. Diabetologia, 10(6) : 948-58.
Han Y,Chen J,Chopra VK,Zhang S,Su G,Ma C .2019 .Alirocumab e cacy and safetyvs. ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. J Clin Lipidol, 10(1) : 98-108.
Chen Y,Yuan Z,Lu J,Eliaschewitz FG,Lorenzatti AJ,Monsalvo ML .2019 .Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Pre-speci ed analysis of the Chinese population from the BERSON clinical trial. Diabetes Obes Metab, 10(6) : 1464-73.
Schwartz GG,Steg PG,Szarek M,Bhatt DL,Bittner VA,Diaz R .2018 .Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med, 10(22) : 2097-107.
Hao Y,Yang YL,Wang YC,Li J. .2022 .E ect of the early application of evolocumab on blood lipid pro le and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome. Int Heart J, 10(4) : 052-77.
Janik MJ,Urbach DV,van Nieuwenhuizen E,Zhao J,Yellin O,Dinet MTB .2021 .Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: A prospective, randomised, placebo-controlled study. Atherosclerosis, 06 : 20-7.
Raal FJ,Kallend D,Ray KK,Turner T,Koenig W,Wright RS .2020 .Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med, 10(16) : 1520-30.
Ray KK,Wright RS,Kallend D,Koenig W,Leiter LA,Raal FJ .2020 .Two ohase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med, 10(16) : 1507-19.
Huo Y,Chen B,Lian Q,Wang S,Liu L,Lu D . .Tafolecimab in Chinese patients with non-familial hypercholes-. , : .
Leiter LA,Wieland DM,Baccara-Dinet MT,Letierce A,Samuel R .2018 .E cacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: A pooled analysis of 10 phase III ODYSSEY clinical trials. Diabet Med, 10(1) : 121-30.
Cao YX,Liu HH,Dong QT,Li S,Li JJ .2018 .E ect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis. Diabetes Obes Metab, 10(6) : 1391-8.
Mansi IA,Chansard M,Lingvay I,Zhang S,Halm EA .2021 .Association of statin therapy initiation with diabetes progression: A retrospective matched-cohort study. JAMA Intern Med, 5714(12) : 1562-74.
Sattar N,Preiss D,Murray HM,Welsh P,Buckley BM,de Craen AJ .2010 .Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet, 6736(09) : 61965-6.
Casula M,Mozzanica F,Scotti L,Tragni E,Pirillo A,Corrao G .2017 .Statin use and risk of new-onset diabetes: A metaanalysis of observational studies. Nutr Metab Cardiovasc Dis, 03(5) : 396-406.
Laakso M,Kuusisto J,Stancakova A,Kuulasmaa T,Pajukanta P,Lusis AJ .2017 .The METSIM study: A resource for studies of metabolic and cardiovascular diseases. J Lipid Res, 10(3) : 481-93.
Nicholls SJ,Puri R,Anderson T,Ballantyne CM,Cho L,Kastelein JJ .2016 .E ect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomised clinical trial. JAMA, 316(22) : 2373-84.
.2016 .. doi: 10, 16951 : .
Da Dalt L,Ruscica M,Bonacina F,Balzarotti G,Dhyani A,Di Cairano E .2019 .PCSK9 de ciency reduces insulin secretion and promotes glucose intolerance: The role of the lowdensity lipoprotein receptor. Eur Heart J, 10(4) : 357-68.
Wong ND,Sattar N. .2023 .Cardiovascular risk in diabetes mellitus: Epidemiology, assessment and prevention. Nat Rev Cardiol, 10(10) : z-95.
Sabatine MS,Giugliano RP,Keech AC,Honarpour N,Wiviott SD,Murphy SA .2017 .Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 10(18) : 1713-22.
Zhang XL,Zhu QQ,Zhu L,Chen JZ,Chen QH,Li GN .2015 .Safety and e cacy of anti-PCSK9 antibodies: A analysis of 25 randomised, controlled trials. BMC Med, 10 : 123.
Blom DJ,Koren MJ,Roth E,Monsalvo ML,Djedjos CS,Nelson P .2017 .Evaluation of the e cacy, safety and glycaemic e ects of evolocumab (AMG 145) in hypercholesterolaemic patients strati ed by glycaemic status and metabolic syndrome. Diabetes Obes Metab, 10(1) : 98-107.
Cariou B,Leiter LA,Wieland DM,Bigot G,Colhoun HM,Prato SD .2017 .E cacy and safety of alirocumab in insulintreated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial. Diabetes Metab, 01(5) : 453-9.
'Donoghue O,Giugliano ML,Wiviott RP,Atar SD,Keech D,Kuder A,JF A .2022 .Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation, 10(15) : 1109-19.
Ballantyne CM,Banka P,Mendez G,Garcia R,Rosenstock J,Rodgers A .2023 .Phase 2b randomised trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol, 02(16) : 1553-64.
Patel RS,Scopelliti EM,Olugbile O. .2018 .The role of PCSK9 inhibitors in the treatment of hypercholesterolemia. Ann Pharmacother, 10(10) : 1000-18.
0

Citations

0

Downloads

50

Views